Crucell Terug naar discussie overzicht

Pfizer bevestigt overnamebod $68 mrd op Wyeth

1. [verwijderd] 26 maart 2009 14:19

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Pfizer Announces Completion of $13.5 Billion Debt Offering
   
   Last update: 3/25/2009 8:30:03 AM
   
   NEW YORK, Mar 25, 2009 (BUSINESS WIRE)
   
   -- Pfizer today announced the successful completion of its offering of $13.5 billion of senior unsecured notes. The notes consist of:
   
   -- $1.25 billion of floating rate notes due 2011
   
   -- $3.50 billion of 4.45% notes due 2012
   
   -- $3.00 billion of 5.35% notes due 2015
   
   -- $3.25 billion of 6.20% notes due 2019
   
   -- $2.50 billion of 7.20% notes due 2039.
   
   Pfizer intends to use the net offering proceeds for general corporate purposes, including funding a portion of the purchase price of the proposed Wyeth acquisition and the refinancing of existing debt. Pfizer may also temporarily invest funds that are not immediately needed for these purposes in short-term marketable securities.
2. [verwijderd] 29 maart 2009 14:02

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Pfizer Faced Financing Worry, Possible Rival in Wyeth Purchase
   
   By Shannon Pettypiece and Tom Randall
   
   March 28 (Bloomberg) -- Wyeth Chief Executive Officer Bernard Poussot will get about $53 million if he is terminated after his company is sold to Pfizer Inc. in a deal that sometimes stalled during eight months of negotiations.
   
   Talks between Poussot, 57, and Pfizer CEO Jeffrey Kindler, 53, broke down in October when Kindler told Poussot he didn’t think he could obtain financing because of the meltdown in the banking industry, according to a U.S. regulatory filing. The acquisition almost fell apart again in December, when an unnamed rival drugmaker considered making a bid.
   
   Wyeth, based in Madison, New Jersey, agreed on Jan. 26 to sell itself to New York-based Pfizer in a transaction valued at about $64 billion. Pfizer, the world’s biggest drugmaker, gains access to Wyeth’s vaccines, consumer products and experimental biotechnology treatments with the purchase. Poussot, named Wyeth CEO in 2008, will get an exit package of $24.3 million if he’s terminated after the sale closes, and $28.8 million in cash for stock, options and incentives, the filing said.
   
   “I’d guess Poussot isn’t going to retire,” once he leaves the combined company, said Les Funtleyder, an analyst with Miller Tabak & Co. in New York, in a telephone interview. “I expect this newer generation of CEOs to stay around. Health care is a $2 trillion, very fragmented and confused industry that needs good management, so there are plenty of opportunities.”
   
   Poussot’s package includes $18.5 million when previously awarded stock and options are cashed out, and $10.3 million in long-term incentives that he may claim immediately after termination, or otherwise vest in three years if he stays on, the Securities and Exchange Commission filing said.
   
   Timing Unclear
   
   It isn’t clear when Poussot, who joined Wyeth in 1986 as general manager in France and rose to chief operating officer in January 2007, will leave the combined company.
   
   “The future of all Wyeth executives is part of our ongoing discussions with Pfizer, and no decisions have been announced,” said a Wyeth spokesman, Doug Petkus, in a telephone interview yesterday.
   
   Pfizer fell 34 cents, or 2.4 percent, to $14.04 in New York Stock Exchange composite trading yesterday. Wyeth shares fell 44 cents, or 1 percent, to $43.11.
   
   The regulatory filing is “another significant milestone related to our proposed acquisition of Wyeth,” Pfizer spokeswoman Joan Campion said in a telephone interview yesterday.
   
   Wyeth’s Petkus said the Pfizer acquisition offered “an excellent strategic fit” for Wyeth. “Our board deliberated the situation, considered many factors and concluded at the time that the Pfizer offer was in the best interest of our shareholders,” he said.
   
   Sept. 9 Bid
   
   The courtship began June 6, when Kindler contacted Poussot to request a meeting. Pfizer then proposed buying Wyeth on Sept. 9 for $53 a share, the regulatory filing said. That would have been a 28 percent premium over Wyeth’s closing stock price the previous day. Wyeth’s board concluded the offer was “deficient,” Poussot told Kindler in a Sept. 26 phone call.
   
   On Oct. 14, Kindler returned to Poussot, telling him he didn’t believe it was feasible to get the necessary financing, given the market conditions. Poussot then said it wasn’t “practical” to continue talks, according to the filing.
   
   On Nov. 5, after Wyeth’s stock had fallen about 20 percent since the initial offer, Kindler returned once again. This time, he dropped his offer to $46 a share, a 31 percent premium over the previous day’s closing price. That offer, too, was rejected by the Wyeth board, which said the bid “significantly undervalued” the company, the filing said.
   
   ‘Company X’
   
   About a month later, on Dec. 16, a rival drugmaker, identified only as “Company X” in the filing, contacted Wyeth’s banker, Morgan Stanley, and asked if it “could participate in a sale process if one were taking place,” according to the filing.
   
   This company said the most it was willing to pay per share was in the “mid-$40s,” the filing said.
   
   Pfizer’s and Wyeth’s boards then agreed to a price of $50.19 a share in cash and stock, the filing said.
   
   To contact the reporter on this story: Shannon Pettypiece in New York at spettypiece@bloomberg.net; Tom Randall in New York at trandall6@bloomberg.net.
   
   Last Updated: March 28, 2009 00:00 EDT
   
   www.bloomberg.com/apps/news?pid=20601...
3. aossa 29 maart 2009 15:34

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 23 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Uit vorig artikel:
   
   

   quote:

   schreef:

   ‘Company X’
   
   About a month later, on Dec. 16, a rival drugmaker, identified only as “Company X” in the filing, contacted Wyeth’s banker, Morgan Stanley, and asked if it “could participate in a sale process if one were taking place,” according to the filing.
   
   This company said the most it was willing to pay per share was in the “mid-$40s,” the filing said.
   
   Pfizer’s and Wyeth’s boards then agreed to a price of $50.19 a share in cash and stock, the filing said.
   
   www.bloomberg.com/apps/news?pid=20601...

   De gesprekken met Crucell (bekend gemaakt ergens begin jan09) moeten ongetwijfeld van doen hebben gehad met het voorstel van 'The Mystery X'.
   
   'Waarom' blijft de vraag ...
4. [verwijderd] 1 april 2009 12:48

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   WSJ: Abbott kicked tires at Wyeth
   March 31, 2009 — 10:35am ET | By Tracy Staton
   Remember the suitor that briefly threatened to disrupt the Pfizer-Wyeth courtship? Well, the Wall Street Journal reports today that Company X is Abbott Laboratories. The company approached Wyeth in mid-December, but decided not to make a bid "amid concerns over price and other issues," the paper reports.
   
   According to Pfizer's SEC filing revealing details about the Wy-Pfi deal, Company X (a.k.a. Abbott) told Wyeth that its top offer could only be a "mid-$40s" price per share. Pfizer ended up making a deal for $50.19 per share.
   
   Besides price, Abbott was worried that a big deal might depress its stock, the WSJ's sources said. Abbott has less cash on hand than Pfizer, which boasts the biggest war chest in pharma. Plus, Abbott's Humira competes with Enbrel, the anti-inflammatory Wyeth sells in partnership with Amgen. The Enbrel partnership agreement has some sticky provisions that take effect if Wyeth sells or distributes a rival product.
   
   Nonetheless, Abbott's interest in Wyeth could mean that it would entertain other big acquisitions. An Abbott spokeswoman told the Health Blog that the company isn't into large acquisitions, however. But she also declined to comment on whether Abbott is/was Company X.
   
   - read the WSJ story
   
   www.fiercepharma.com/story/wsj-abbott...
5. aossa 7 april 2009 15:31

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 23 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Pfizer announces post-Wyeth deal organization plan
   Pfizer will focus on traditional, biotech drugs after Wyeth buyout, while retaining key execs
   Tuesday April 7, 2009, 9:07 am EDT
   
   NEW YORK (AP) -- Pfizer Inc. said Tuesday it will form two main research units after completing the buyout of Wyeth, focusing on traditional pharmaceuticals and cutting-edge biotechnology drugs.
   
   Pfizer will also keep several key executives from Madison, N.J.-based Wyeth as part of its increased focus on the field of biotechnology, which uses living cells to make treatments for a wide range of conditions, including cancer.
   
   "Creating two distinct, but complementary, research organizations, led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery," Pfizer Chief Executive Jeff Kindler said in a statement.
   
   The company's planned PharmaTherapeutics Research Group will be headed by Martin Mackay, the current leader of Pfizer's global research and development unit. The current president of Wyeth research, Mikael Dolsten, will head the biotechnology unit. Meanwhile, Pfizer said it will keep eight senior Wyeth executives including Emilio Emini, who will head vaccine research, and Menelas Pangalos, who will head neuroscience.
   
   Kindler will be CEO of the combined company. Pfizer did not say whether Wyeth CEO Bernard Poussot would have a role after the deal closes.
   
   "He is an instrumental part of our integration efforts and will continue to provide us with critical counsel and support until the close of the acquisition," Kindler said.
   
   Pfizer currently makes blockbuster drugs including the impotence treatment Viagra, antidepressant Zoloft and pain relievers Celebrex and Lyrica. Its expansion into biotechnology is part of a trend across the industry as large pharmaceutical companies face patent losses and generic competition on key revenue drivers.
   
   Pfizer's cholesterol drug Lipitor, the world's top-selling drug, now provides just over one-quarter of all company revenue with nearly $13 billion in annual sales. Sales are expected to plummet when the that drug loses patent protection in November 2011.
   
   By purchasing Wyeth, the company can add new programs and moneymaking products, while cutting costs. Wyeth blockbusters include the antidepressant Effexor and children's vaccine Prevnar.
   
   The $68 billion cash, stock and debt deal, made on Jan. 26, is still pending. The deal's total value, though, is actually less than the original offer because the value of Pfizer shares has fallen since the offer was made.
   
   The combined company will have nine businesses, including the biotech business, primary care, and consumer health. The deal is expected to close during the third or fourth quarter
   
   finance.yahoo.com/news/Pfizer-announc...
6. josti5 7 april 2009 15:34

   auteur info

   • josti5

     Lid sinds: 23 feb 2005

     Laatste bezoek: 25 mrt 2025

   • Aanbevelingen

     Ontvangen: 17886

     Gegeven: 21100

   •    Aantal posts: 34.559

   Héééél interessant!
7. aossa 7 april 2009 15:36

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 23 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Press Release Source: Pfizer Inc
   Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition
   Innovative Approach to Research Supporting Nine Diverse Businesses: Primary Care, Specialty Care & Vaccines, Emerging Markets, Oncology, Established Products, Animal Health, Capsugel, Consumer Health, Nutritional Health
   
   Tuesday April 7, 2009, 9:00 am EDT
   
   NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE - News) today announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes.
   
   The company will establish a unique research model designed to advance the strong scientific capabilities of both Pfizer and Wyeth (NYSE: WYE - News) and to support the new company’s nine diverse health care businesses. At the senior-most level of the organization, Pfizer will retain eight senior executives from Wyeth who will join the company post-closing.
   
   CEOs Jeff Kindler and Bernard Poussot and senior leadership of both companies continue to work closely together through the integration process. As planning continues, additional appointments are expected that will enable Pfizer to begin appreciating the benefits of the combined company with a new team and structure in place immediately following the close of the acquisition.
   
   A New Approach for Research
   
   To maximize new opportunities in biopharmaceutical research, Pfizer will form two distinct research organizations. The PharmaTherapeutics Research Group will focus on the discovery of small molecules and related modalities and will be led by Martin Mackay, who now leads Pfizer Global Research & Development (PGRD). The BioTherapeutics Research Group will focus on large-molecule research, including vaccines, and will be led by Mikael Dolsten, who currently serves as President of Wyeth Research. Both Dr. Dolsten and Dr. Mackay will serve as presidents of their respective organizations and members of Pfizer’s Executive Leadership Team, and both will report to Pfizer Chairman and Chief Executive Officer Jeff Kindler.
   
   The new BioTherapeutics Research Group will capitalize on Wyeth’s industry-leading expertise in biologics and build on the momentum established by both Pfizer’s Biotherapeutics and Bioinnovation Center (BBC) and centers of large-molecule research and pharmaceutical science excellence in PGRD, which will be part of the new, larger group. This new group’s mandate will be to create a broad and deep pipeline in vaccines, antibodies, proteins, peptides, nucleic acids and other novel modalities. The PharmaTherapeutics Research Group will continue to advance the strong legacy of both Pfizer and Wyeth in small-molecule discovery.
   
   Within these two research groups, small, focused scientific teams — targeting specific high-potential therapeutic areas and leading-edge innovative technologies — will be led by world-class Chief Scientific Officers who will act as single points of accountability for delivering medical advances on behalf of the company. These teams will be responsible for creating a rich portfolio of both small and large molecules from across both research organizations and, in particular, with delivering positive proofs-of-concept for Pfizer’s business units to develop. They will also aggressively pursue collaborations with top academic, public-sector and private-sector institutions to accelerate research and development of new medicines.
   
   The combined scientific teams and programs of the two companies will enable Pfizer to make significant advances in vaccines and neuroscience, among many other areas of unmet medical need. In that connection, Emilio Emini, who currently heads Wyeth’s Vaccine Research; and Development, will join Pfizer as Chief Scientific Officer, Vaccine Research, and Menelas Pangalos, who currently serves as Wyeth’s Head of Discovery, will join Pfizer as Chief Scientific Officer, Neuroscience Research. Dr. Emini and Dr. Pangalos bring incomparable scientific expertise and outstanding leadership to Pfizer, which are essential to building the world’s premier biopharmaceutical research and development organization.
   
   Additionally, Pfizer will form a team of top scientists from both companies who will seek and evaluate new technologies, platforms and pre-proof-of-concept small and large molecules from external sources. As this group identifies promising early-stage candidates from outside the company, it will collaborate with Pfizer’s business development team to pursue these opportunities. By complementing Pfizer’s internal research efforts, these scientists will help assure Pfizer has access to the broadest set of early stage compounds and technologies available to find new medicines for patients.
   
   “Creating two distinct, but complementary, research organizations, led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery,” Mr. Kindler said. “This structure powerfully states our commitment to becoming the industry leader in small molecules, large molecules and vaccines. Our approach to research will fuel our discovery efforts, inspire top talent and translate into high-impact new medicines for patients. I am honored that world-class scientists like Drs. Dolsten, Emini and Pangalos will be joining the outstanding scientists at Pfizer and, as we continue our integration planning, I look forward to our welcoming many more distinguished Wyeth scientists to our organization.”
   
   Enhanced Commercial Operating Structure
   
   The new Pfizer will consist of nine diverse global health care businesses. As is the case at Pfizer today, the leader of each of the company’s biopharmaceutical businesses will have clear accountability for results from initial product development to providing access to patients and through to the end of the product’s life cycle. The businesses will be led by world-class executives from both Pfizer and Wyeth who will have the resources to pursue attractive growth opportunities and to meet the needs of patients and customers around the world.
   
   Ian Read, currently President of Worldwide Pharmaceutical Operations for Pfizer, will become Group President, Pfizer BioPharmaceutical Businesses, and remain a member of the Executive Leadership Team reporting to Mr. Kindler. In that capacity, he will lead a group that includes five leading biopharmaceutical businesses:
   
   Primary Care, led by President Olivier Brandicourt, will be the world’s leading primary care business, with strong positions in cardiovascular (#1), infectious disease (#2), immunology (#4) and central nervous system diseases (#2), and with unique research and development opportunities in areas like Alzheimer’s disease and pain.
   Specialty Care and Vaccines will be led by President Geno Germano, currently President of Wyeth’s U.S. and Pharmaceuticals business units. It will be the world’s second largest specialty care business, with prominent positions in inflammation (#2), vaccines (#4) and immunology (#4); leading products such as Enbrel, the world’s leading biologic and Prevnar, the world’s leading vaccine; and a strong pipeline of small- and large-molecule compounds.
   
   vervolg zie: finance.yahoo.com/news/Pfizer-Announc...
8. [verwijderd] 7 april 2009 15:42

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ik heb mindere inhoud gelezen vandaag en eerlijk is eerlijk ook gepost.
   
   Something is cooking.
9. aossa 7 april 2009 15:45

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 23 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   (het vervolg dan maar)
   ...
   Jim Connolly, currently Wyeth’s Executive Vice President & General Manager, Vaccines, will join the Specialty Care and Vaccines Business Unit as President, Vaccines, reporting to Mr. Germano. He will lead an integrated vaccine business comprising marketing, sales and medical affairs, which will align closely with the Vaccine Research group led by Dr. Emini. They will work together to bring innovative new vaccines to patients around the globe.
   
   Emerging Markets will continue to be led by President Jean-Michel Halfon and will have a significantly enhanced presence in high-growth, less-developed and under-penetrated markets, including those in Latin America, the Middle East and China.
   Oncology will continue to be led by President Garry Nicholson and will continue to bring patients important treatments like Sutent. It will also bring to market one of the most robust oncology product pipelines in the biopharmaceutical industry, one that includes compounds focusing on diverse tumor types including lung, colorectal, liver, prostate and breast.
   Established Products will continue to be led by President David Simmons and will continue to be a strong global business in a marketplace that is expected to see significant growth in the years ahead. Through portfolio enhancement and expansion activities, including new partnerships, Established Products will continue to extend Pfizer’s reach into this important market segment.
   
   Cavan Redmond, currently President of Wyeth’s Consumer Healthcare business, will become Group President, Pfizer Diversified Businesses, join Pfizer’s Executive Leadership Team and report to Mr. Kindler. This group will include four unique businesses, each meeting important customer needs and offering significant growth:
   
   Animal Health will continue to be led by President Juan-Ramón Alaix and will have an enhanced leading position in the industry, with important large animal and companion animal products and a platform that includes vaccines, parasiticides and anti-infectives.
   Capsugel will continue to be led by President Guido Driesen and will continue to be the world's pre-eminent manufacturer and developer of capsule products, equipment and services for the pharmaceutical and associated health care industries.
   Consumer Health will be led by President Paul Sturman, currently President, U.S. and Global Business Development, New Products for Wyeth Consumer Healthcare. Consumer Health will remain a leader in analgesics, cough/cold/allergy and vitamin/nutritional supplements, including brands such as Advil®, Caltrate®, Centrum®, ChapStick®, Robitussin® and ThermaCare®.
   Nutritional Health will be led by President Erica Mann, currently Managing Director of Wyeth Australia and New Zealand. The Nutritional business at Wyeth operates in more than 50 countries and has a portfolio that includes a full line of nutritional products, including infant formulas, follow-on formulas, growing-up milks, and prenatal and adult supplements.
   
   Mr. Kindler stated: “By putting together these businesses and combining in one team a number of strong and experienced Pfizer and Wyeth leaders, we are creating the world’s premier biopharmaceutical company — one that is powerfully positioned to provide substantial value for patients, customers, colleagues and shareholders.”
   
   Integration Progress
   
   Added Chief Financial Officer Frank D’Amelio, who is leading the integration on behalf of Pfizer: “With today’s announcement we have taken another significant step in preparing for the combining of these two great companies. Having our organizational structure in place is critical to the combined company being operational on Day One, and the appointment of these leaders will accelerate our ability to do so.
   
   “We have made substantial progress in a short period of time, particularly in financing, as well as other requirements for closing. Our progress affirms how well these two companies fit together, the value of this combination, and the commitment of our companies to rapid and successful integration,” Mr. D’Amelio said.
   
   Mr. Kindler noted: “I want particularly to thank Wyeth Chief Executive Officer Bernard Poussot for his strong and steady leadership and his partnership. He is an instrumental part of our integration efforts and will continue to provide us with critical counsel and support until the close of the acquisition. Bernard’s commitment to Wyeth leaders and to the success of the combined company is extraordinary.
   
   “We look forward to welcoming these new colleagues and I am confident Pfizer will be strengthened by the addition of many other exceptional Wyeth scientists and business leaders. They will join Pfizer colleagues with whom they share a commitment to delivering the full potential of the Pfizer-Wyeth combination to patients, customers and investors,” Mr. Kindler concluded.
   
   The leadership team will begin working together immediately upon the completion of the acquisition. Until the acquisition is complete, Pfizer and Wyeth leadership will continue in their current roles. Pfizer announced on January 26, 2009, that it is acquiring Wyeth in a cash-and-stock transaction to create the world’s premier biopharmaceutical company. The acquisition remains subject to customary closing conditions, including approval by the stockholders of Wyeth, and regulatory approval in certain jurisdictions. Pfizer and Wyeth continue to expect the transaction to close at the end of the third quarter or during the fourth quarter of 2009.
   
   finance.yahoo.com/news/Pfizer-Announc...
10. josti5 7 april 2009 15:48

    auteur info

    • josti5

      Lid sinds: 23 feb 2005

      Laatste bezoek: 25 mrt 2025

    • Aanbevelingen

      Ontvangen: 17886

      Gegeven: 21100

    •    Aantal posts: 34.559

    Zou die 'biggest deal ever' met Wyeth, waarover Brus het had, nu eindelijk inhoudelijk bekend mogen worden?
    Lijkt mij toch koersgevoelige info...
12. [verwijderd] 7 april 2009 17:04

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    geen hond wil nog een aandeel Crucell
    
    Woefff
13. voda 7 april 2009 17:07

    auteur info

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 25 mrt 2025

    • Aanbevelingen

      Ontvangen: 94242

      Gegeven: 23032

    •    Aantal posts: 385.518

    quote:

    wilb52 schreef:

    geen hond wil nog een aandeel Crucell
    
    Woefff
    

    Wat moet een hond met een aandeel Crucell?
    Die heeft liever een bot. Dat is tenminste nog tastbaar. :-)
14. [verwijderd] 7 april 2009 17:09

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    wilb52 schreef:

    geen hond wil nog een aandeel Crucell
    
    Woefff
    

    Angst voor rabies-vaccin?
    
    Ik zou als hond juist door het dolle heen zijn!
15. [verwijderd] 30 juni 2009 13:51

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    EU: Pfizer/Wyeth Deal Antitrust Probe Extended On Commitments
    
    Last update: 6/30/2009 5:25:47 AMB
    
    RUSSELS (Dow Jones)--The European Commission Tuesday said it has extended by 10 working days its antitrust review into US drugs giant Pfizer Inc.'s (PFE) $68 billion plan to buy out its smaller US rival Wyeth (WYE).
    
    The probe, which is now due to conclude by July 20, has been extended due to commitments offered by the companies to remove any possible bottlenecks to the deal.
    
    Although the commission wouldn't specify what has been offered, commitments usually include divestments in areas of high market concentration. The deal is the largest takeover in the pharmaceutical sector for 10 years.
    
    -By Peppi Kiviniemi and Carolyn Henson, Dow Jones Newswires; +32 2 741 1481; carolyn.henson@dowjones.com (END) Dow Jones NewswiresJune 30,
16. [verwijderd] 17 juli 2009 22:07

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Terwijl er hier alleen maar geleuterd wordt, gaat het nieuws in de farmawereld gewoon door.
    
    :-)
    
    Dirk
    
    Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
    
    Last update: 7/17/2009 1:46:00 PM
    Provides Update on Regulatory Submission in China
    
    NEW YORK, Jul 17, 2009 (BUSINESS WIRE) -- --European Commission Approval Includes Certain Commitments.
    
    Pfizer Inc (PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company's pending acquisition of Wyeth.
    
    The Commission's decision includes Pfizer's commitment to divest certain animal health assets in the EU.
    
    "We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction," said Amy Schulman, senior vice president and general counsel of Pfizer.
    
    In addition, Pfizer announced that China's Ministry of Commerce has extended its review of Pfizer's regulatory submission beyond the initial thirty-day period.
    
    The completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, governmental and regulatory approvals in certain other jurisdictions, and approval by the stockholders of Wyeth.
    
    Ms. Schulman stated, "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close at the end of the third quarter or during the fourth quarter of 2009."
    
    Pfizer Inc: Working together for a healthier world(TM)
17. aossa 21 juli 2009 12:28

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 23 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    Wyeth shareholders vote to be acquired by Pfizer
    98 percent of shareholders of drugmaker Wyeth vote to be acquired by industry giant Pfizer
    
    * By Linda A. Johnson, AP Business Writer
    * On Monday July 20, 2009, 8:18 pm EDT
    
    TRENTON, New Jersey (AP) -- Shareholders of drugmaker Wyeth on Monday voted overwhelmingly to be bought by industry giant Pfizer Inc., pushing aside one of the deal's final hurdles.
    
    More than 98 percent of Wyeth stockholders voted for the $68 billion acquisition, which will solidify Pfizer's standing as the top-selling drugmaker in the world.
    
    The deal transforms New York-based Pfizer overnight from being primarily a maker of the blockbuster pills to a one-stop shop for medical treatments. That's because Wyeth, the No. 12 drugmaker, brings multibillion-dollar products and substantial expertise in creating and manufacturing biologic drugs, vaccines, nonprescription medicines and animal health products.
    
    The tie-up marries Wyeth's blockbuster children's vaccine Prevnar and biologic rheumatoid arthritis drug Enbrel to Pfizer staples such as impotence pill Viagra and cholesterol fighter Lipitor, the world's best-selling drug with about $12.5 billion a year in revenue.
    
    The deal still needs approval by regulators in some foreign countries and by the Federal Trade Commission in the U.S. On Friday, the European Commission granted approval, after requiring the companies to divest some of their animal health businesses.
    
    Boards of both companies have approved the cash-and-stock deal set to close late in the third quarter or in the fourth quarter.
    
    It is one of three mega mergers in the industry announced this year. Swiss drugmaker the Roche Group in March bought the 44 percent of biotech company Genentech it didn't already own for $46.8 billion, and Merck & Co. by year's end is to buy New Jersey neighbor Schering-Plough Corp. for $41.1 billion.
    
    Wyeth's shareholders cast their votes at their annual meeting at a hotel near company headquarters in Madison, New Jersey, although most votes were cast in advance, many by large institutional investors.
    
    "I have mixed feelings" about the deal, Chief Executive and Chairman Bernard Poussot told shareholders, many listening via a Webcast.
    
    Poussot, who will leave once the acquisition is complete, said he had spent 23 years at Wyeth, becoming head of the pharmaceuticals business in 1997, building up a strong executive team and focusing the company on science.
    
    He noted Pfizer will keep several of Wyeth's top scientists. Among them, Mikael Dolsten, president of Wyeth Research, will head up research on vaccines and biologic drugs, and Emilio Emini and Menelas Pangalos will be the chief scientific officers for vaccine research and neuroscience research, respectively.
    
    Plenty of others won't be so lucky.
    
    Pfizer has begun cutting 10 percent of its work force -- about 8,190 jobs -- and expects a staff reduction totaling 15 percent of the combined companies' workers. That implies nearly 20,000 jobs will be eliminated. Wyeth began its own cost-cutting program in January 2008, aiming to eliminate up to 5,000 of its then-50,000 jobs.
    
    A Pfizer spokeswoman said the company would give an update on Wednesday, when it reports its second-quarter earnings. Wyeth issues its report on Thursday.
    
    Pfizer has said those cuts and reducing the number of manufacturing sites from 46 to 41 will bring about $4 billion in cost savings by 2012 and should add to Pfizer's earnings per share in the second full year after closing.
    
    The vote tally came after Poussot told shareholders that Wyeth had the vision to jump into biologic drugs more than a decade ago, build up its vaccine and infant nutrition businesses, and otherwise diversify the company.
    
    Rivals at the top of the pharmaceutical industry are now rushing to do exactly that, and Wyeth's array of technologies and products made it appealing to Pfizer when its CEO, Jeff Kindler, was looking to do a big deal.
    
    "Pfizer, as you know, aggressively pursued us for over seven months," Poussot said.
    
    Wyeth stockholders are to receive the equivalent of $50.19 per share -- a combination of $33.00 in cash and roughly a share of Pfizer common stock. The total was nearly a 15 percent premium to Wyeth's closing price of $43.74 just before the deal was announced on Jan. 26.
    
    Wyeth shares gained 13 cents to close at $46.10 Monday, while Pfizer shares advanced 30 cents, or 2 percent, to $15.26
18. [verwijderd] 21 juli 2009 12:47

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    aossa schreef:

    He noted Pfizer will keep several of Wyeth's top scientists. Among them, Mikael Dolsten, president of Wyeth Research, will head up research on vaccines and biologic drugs, and Emilio Emini and Menelas Pangalos will be the chief scientific officers for vaccine research and neuroscience research, respectively.
    

    Deze heren waren eind 2008 waarschijnlijk meer dan zijdelings betrokken bij de positieve beoordeling van Crucell.
    
    Eind 2009 opnieuw consulteren dan maar?
19. flosz 21 juli 2009 16:14

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    quote:

    munckf schreef:

    [quote=aossa]
    He noted Pfizer will keep several of Wyeth's top scientists. Among them, Mikael Dolsten, president of Wyeth Research, will head up research on vaccines and biologic drugs, and Emilio Emini and Menelas Pangalos will be the chief scientific officers for vaccine research and neuroscience research, respectively.
    [/quote]
    Deze heren waren eind 2008 waarschijnlijk meer dan zijdelings betrokken bij de positieve beoordeling van Crucell.
    
    Eind 2009 opnieuw consulteren dan maar?
    

    Uit 2004:
    "As part of IAVI's continuing effort to expand and improve the development pipeline, we are pleased to work with Crucell in applying their critical technology to help advance the development of an AIDS vaccine," said Emilio Emini, IAVI's Senior Vice President, Vaccine Development.
    investors.crucell.com/C/132631/PR/200...
    
    Uit 2001:
    During the first public presentation of animal and cellular immune response data delivered yesterday at the Keystone Symposium in Keystone, Colorado, Dr. Emilio Emini, who heads Merck's HIV-vaccine research, described the experiments that led Merck to begin human testing of the experimental AIDS vaccine in February. In his presentation, Dr. Emini showed that the adenovirus based vaccine provoked a killer-cell response sufficiently strong in monkeys exposed to the AIDS-like virus, that they remained healthy, even though they still harbor small amounts of the virus.
    investors.crucell.com/C/132631/PR/200...
    
20. [verwijderd] 21 juli 2009 20:32

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    flosz schreef:

    [quote=munckf]
    [quote=aossa]
    He noted Pfizer will keep several of Wyeth's top scientists. Among them, Mikael Dolsten, president of Wyeth Research, will head up research on vaccines and biologic drugs, and Emilio Emini and Menelas Pangalos will be the chief scientific officers for vaccine research and neuroscience research, respectively.
    [/quote]
    Deze heren waren eind 2008 waarschijnlijk meer dan zijdelings betrokken bij de positieve beoordeling van Crucell.
    
    Eind 2009 opnieuw consulteren dan maar?
    [/quote]
    Uit 2004:
    "As part of IAVI's continuing effort to expand and improve the development pipeline, we are pleased to work with Crucell in applying their critical technology to help advance the development of an AIDS vaccine," said Emilio Emini, IAVI's Senior Vice President, Vaccine Development.
    investors.crucell.com/C/132631/PR/200...
    
    Uit 2001:
    During the first public presentation of animal and cellular immune response data delivered yesterday at the Keystone Symposium in Keystone, Colorado, Dr. Emilio Emini, who heads Merck's HIV-vaccine research, described the experiments that led Merck to begin human testing of the experimental AIDS vaccine in February. In his presentation, Dr. Emini showed that the adenovirus based vaccine provoked a killer-cell response sufficiently strong in monkeys exposed to the AIDS-like virus, that they remained healthy, even though they still harbor small amounts of the virus.
    investors.crucell.com/C/132631/PR/200...
    
    

    Ongelofelijk weer! Hoe krijg je het voor elkaar?!
21. [verwijderd] 30 september 2009 12:40

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pfizer Gets Australia Clearance To Acquire Wyeth
    Last update: 9/30/2009 6:06:21 AM
    
    Pfizer Inc. (PFE), a New York health-care company, said Wednesday that Australian antitrust authorities cleared it to acquire Wyeth (WYE), a Madison, N.J., health-care company. Australia's Competition and Consumer Commission cleared the deal on the condition that Pfizer divest itself of certain animal-health assets in Australia. The deal remains subject to regulatory clearance in the U.S. and Canada, approvals Pfizer said it expects to receive shortly. Pfizer said it hopes to close the deal early in the fourth quarter. -Robert Daniel; 415-439-6400;
    
    AskNewswires@dowjones.com (END) Dow Jones NewswiresSeptember 30, 2009 06:06 ET (10:06 GMT)